Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of multiple myeloma
• •* Relapsed or refractory disease
• •Measurable or evaluable disease as defined by at least 1 of the following:
• •* Serum monoclonal protein ≥ 1.0 g by protein electrophoresis
• •* Monoclonal protein ≥ 200 mg by 24-hour urine electrophoresis
• •* Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
• •* Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)
• •Previously treated disease
• •* No limit to prior therapy provided there is adequate residual organ function
• •Must have undergone hematopoietic stem cell collection (for transplant candidates) OR not considered to be a hematopoietic stem cell transplant candidate
• •PATIENT CHARACTERISTICS:
• •ECOG performance status (PS) 0-2 (ECOG PS of 3 allowed if secondary only to pain)
• •Platelet count ≥ 75,000/mm\^3
• •Hemoglobin ≥ 8.0 g/dL (transfusion allowed)
• •ANC ≥ 1,000/mm\^3
• •Creatinine ≤ 3 mg/dL
• •Calcium ≤ 15 mg/dL
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 4 weeks after completion of study therapy
• •No impending long bone fracture
• •No other active malignancy except nonmelanoma skin cancer, carcinoma in situ of the cervix, or breast cancer
• •No uncontrolled infection
• •No known hypersensitivity to any of the components of study drugs
• •No other co-morbidity that would preclude study participation
• •PRIOR CONCURRENT THERAPY:
• •Recovered from prior surgery, radiotherapy, or other antineoplastic therapy
• •No prior samarium Sm 153 lexidronam pentasodium or strontium chloride Sr 89
• •At least 3 weeks since prior myelosuppressive agents
• •At least 2 weeks since prior nonmyelosuppressive agents (e.g., thalidomide)
• •At least 2 weeks since prior and no concurrent high-dose corticosteroids
• •* Chronic steroids (maximum dose of 20 mg/day prednisone or equivalent) allowed for disorders other than myeloma (i.e., adrenal insufficiency or rheumatoid arthritis)
• •At least 30 days since prior and no other concurrent investigational therapy
• •No concurrent external beam radiotherapy
• •No concurrent cytotoxic chemotherapy
• •No other concurrent systemic antineoplastic therapy including, but not limited to, any of the following:
• •* Immunotherapy
• •* Hormonal therapy
• •* Monoclonal antibody therapy